The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.

Company Guidance -

Q2 2025

During the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call, extensive guidance was provided regarding the company's strategic and operational plans. The company announced the U.S. FDA clearance to initiate a pivotal Phase 3b trial for their NurOwn technology, aimed at treating early-stage ALS patients, marking a significant regulatory milestone. Additionally, they plan to initiate manufacturing at the Tel Aviv Sourasky Medical Center, with a subsequent technology transfer to Pluri for expanded cleanroom facilities. The trial, named ENDURANCE, is designed under a Special Protocol Assessment (SPA) with the FDA to mitigate regulatory risks. Approximately 15 leading clinical centers across the U.S. are poised to participate in the trial, with ongoing negotiations for clinical trial agreements. The company also highlighted the financial constraints and ongoing efforts to secure strategic funding, including a $15 million non-dilutive grant under review. These initiatives underscore the company's commitment to developing innovative therapeutic options for ALS within a challenging financial environment.

Regulatory Clearance for Phase 3b Trial

The U.S. FDA has cleared Brainstorm Cell Therapeutics to initiate the Phase 3b trial for NurOwn, marking a significant milestone in their ALS treatment development.

Strong Interest from Clinical Sites

Brainstorm is negotiating with approximately 15 leading clinical centers across the United States for their Phase 3b trial, highlighting strong interest and support from renowned ALS clinicians and researchers.

Positive Biomarker Research

Significant changes in biomarkers were observed in the study, showing NurOwn's potential multimodal mechanism of action, including neuroprotective and anti-inflammatory effects.

Exosome Program Progress

Promising preclinical data from Brainstorm's exosome program demonstrates therapeutic effects in models of lung disease, with active pursuit of strategic partnerships for clinical development.

Brainstorm Cell Therapeutics (BCLI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCLI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 18, 2025	2025 (Q2)	-0.37 / -	0.6	―	―	―
May 16, 2025	2025 (Q1)	- / -0.45	-0.75	40.00% (+0.30)	―
Mar 31, 2025	2024 (Q4)	-0.97 / -0.45	-0.75	40.00% (+0.30)	―
Nov 14, 2024	2024 (Q3)	-0.57 / -0.51	-0.45	-13.33% (-0.06)	―	―
Aug 14, 2024	2024 (Q2)	-0.53 / 0.60	-1.95	130.77% (+2.55)	―
May 14, 2024	2024 (Q1)	- / -	-0.14	―	―	―
Apr 01, 2024	2023 (Q4)	-1.05 / -0.75	-2.1	64.29% (+1.35)	―	―
Nov 14, 2023	2023 (Q3)	-2.25 / -0.45	-2.85	84.21% (+2.40)	―
Aug 14, 2023	2023 (Q2)	-2.17 / -1.95	-2.85	31.58% (+0.90)	―
May 15, 2023	2023 (Q1)	-2.48 / -2.10	-2.25	6.67% (+0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCLI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 16, 2025	$1.16	$1.32	+13.79%
Mar 31, 2025	$1.19	$1.26	+5.88%
Nov 14, 2024	$1.13	$1.21	+7.08%
Aug 14, 2024	$4.78	$4.58	-4.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Brainstorm Cell Therapeutics (BCLI) report earnings?

Brainstorm Cell Therapeutics (BCLI) is schdueled to report earning on Aug 18, 2025, Before Open (Confirmed).

What is Brainstorm Cell Therapeutics (BCLI) earnings time?

Brainstorm Cell Therapeutics (BCLI) earnings time is at Aug 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BCLI EPS forecast?

BCLI EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing